Saturday 17 October 2026
Export DLB’s income statement to Excel — free account
Dolby Laboratories
DLB Industrials Specialty Business Services
Dolby Laboratories' revenue for fiscal 2025 (year ended September 2025) was $1.3 billion, up 5.92% from fiscal 2024. In the quarter to June 2026, revenue fell 3.34%, EPS fell 37.5% and free cash flow grew 157.4%, each against the same quarter a year earlier. Dividend growth for ten consecutive years.
59.95
0.88
−1.45%
Follow DLB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
22.09 | 23.46 | 25.59 | 27.21 |
+8 more quarters Free account |
P/S ratio |
3.66 | 4.19 | 4.58 | 5.14 | |
P/FCF ratio |
13.72 | 21.60 | 15.87 | 16.13 | |
P/Operating CF |
29.59 | 61.82 | 111.88 | 56.48 | |
P/B ratio |
1.91 | 2.18 | 2.36 | 2.64 | |
Price to Tangible BV |
2.95 | 3.35 | 3.59 | 4.07 | |
EV/Sales |
3.11 | 3.70 | 4.04 | 4.55 | |
EV/EBITDA |
12.31 | 14.21 | 15.55 | 16.90 | |
EV/Operating CF |
9.63 | 14.93 | 12.86 | 13.01 | |
EV/FCF |
11.67 | 19.06 | 13.99 | 14.28 | |
Quick Ratio |
2.46 | 2.25 | 2.48 | 2.57 | |
Current Ratio |
3.19 | 2.98 | 3.17 | 3.17 | |
Net Debt/EBITDA |
(12.45) | (4.82) | (8.19) | (14.64) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.43 | 0.42 | 0.42 | 0.43 | |
Operating CF/Net income |
5.85 | 0.97 | 1.03 | 2.49 | |
Capex/Depreciation |
(0.39) | (1.72) | 0.05 | (0.89) | |
Research and Development Expense of Revenue |
21.56% | 16.09% | 19.92% | 21.97% | |
Selling, General and Administrative Expense of Revenue |
52.67% | 43.50% | 46.67% | 53.49% | |
Intangible Assets out of Total Assets |
0.29 | 0.28 | 0.28 | 0.29 | |
Share Based Compensation of Revenue |
10.15% | 7.76% | 10.73% | 10.11% | |
Graham Net Nets |
0.15 | 0.14 | 0.13 | 0.11 | |
Graham Number |
38.38 | 39.87 | 39.24 | 40.54 | |
Earnings Yield |
4.53% | 4.26% | 3.91% | 3.68% | |
Free Cash Flow Yield |
7.29% | 4.63% | 6.30% | 6.20% | |
Revenue per Share |
3.24 | 4.16 | 3.63 | 3.20 | |
Operating CF per Share |
1.78 | 0.97 | 0.57 | 1.28 | |
Capex per Share |
(0.10) | (0.48) | 0.01 | (0.23) | |
Free Cash Flow per Share |
1.67 | 0.49 | 0.59 | 1.05 | |
Cash per Share |
7.85 | 7.08 | 7.63 | 8.28 | |
Shareholders Equity per Share |
27.51 | 27.59 | 27.26 | 27.45 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
27.51 | 27.59 | 27.26 | 27.45 | |
Free Cash Flow |
157.67 | 46.42 | 56.04 | 100.99 | |
Working Capital |
909.71 | 940.10 | 964.56 | 950.47 | |
Capital Expenditures |
(9.79) | (46.09) | 1.25 | (21.84) | |
Net Current Asset Value |
762.15 | 792.35 | 818.81 | 792.45 | |
EV/EBIT |
17.63 | 19.98 | 21.85 | 23.19 | |
Capex to Sales |
0.03 | 0.12 | 0.00 | 0.07 | |
Price to Operating Income |
20.72 | 22.66 | 24.80 | 26.19 | |
| Other line items | |||||
Average Receivables |
291.38 | 352.70 | 356.20 | 323.28 | |
Average Payables |
14.85 | 18.99 | 10.11 | 17.61 | |
Average Inventory |
31.59 | 33.26 | 31.55 | 32.08 | |
Average Assets |
3,176.30 | 3,239.27 | 3,175.36 | 3,168.84 | |
Average Common Equity |
2,603.48 | 2,605.08 | 2,559.95 | 2,559.42 |
Columns are period end dates